

UC San Diego

UC San Diego Previously Published Works

Title

Ibrutinib Efficacy Across Subgroups of Patients With High-Risk Chronic Lymphocytic Leukemia: A Systematic Literature Review

Permalink

<https://escholarship.org/uc/item/8xv8m1mq>

Journal

Clinical Lymphoma Myeloma & Leukemia, 24

ISSN

2152-2650

Authors

Allan, John N

Kipps, Thomas J

Bokun, Alex

et al.

Publication Date

2024-09-01

DOI

10.1016/s2152-2650(24)00589-5

Copyright Information

This work is made available under the terms of a Creative Commons Attribution License, available at <https://creativecommons.org/licenses/by/4.0/>

Peer reviewed

POSTER: CLL-479

6-Year Time to Next Treatment (TTNT) Extrapolation Curve for GLOW Study: First-Line Ibrutinib Plus Venetoclax (I+V) Offers Long Treatment-Free Period for Older Adult/Unfit Patients With Chronic Lymphocytic Leukemia (CLL)

Santiago Ossorio Prendes MD¹, Vicente Gimeno PharmD, PhD², Jose Angel Hernandez Rivas MD, PhD³, Francisco Javier Lopez Jimenez MD⁴, Joris Diels BS⁵, Claudio Schioppa PhD⁵, Ana Alfayate Lobo MD⁶, Teresa Domínguez-Lubillo MS⁷

¹Hospital General Universitario Gregorio Marañón, Department of Hematology, Madrid, Spain. ²Hospital Universitario Miguel Servet, Pharmacy Department, Zaragoza, Spain. ³Hospital Universitario Infanta Leonor, Department of Hematology, Madrid, Spain. ⁴Hospital Universitario Ramón y Cajal, Department of Hematology, Madrid, Spain. ⁵Janssen Pharmaceutica N.V, Beerse, Belgium. ⁶Johnson & Johnson Company, Janssen Scientific Affairs, Madrid, Spain. ⁷Johnson & Johnson Company, Health Economics & Market Access, Madrid, Spain

POSTER: CLL-481

Ibrutinib Efficacy Across Subgroups of Patients With High-Risk Chronic Lymphocytic Leukemia: A Systematic Literature Review

John N. Allan MD¹, Thomas J. Kipps MD, PhD², Alex Bokun PharmD³, Rodrigo Maegawa MD³, Susan M. O'Brien MD⁴

¹Weill Cornell Medicine, New York, USA. ²University of California San Diego, Moores Cancer Center, San Diego, USA. ³Janssen Scientific Affairs, LLC, a Johnson & Johnson company, Titusville, USA. ⁴University of California Irvine, Chao Family Comprehensive Cancer Center, Irvine, USA

POSTER: CLL-487

First-Line Fixed-Duration Ibrutinib Plus Venetoclax (Ibr+Ven) vs Chlorambucil Plus Obinutuzumab (Clb+O): 55-Month Follow-Up From the GLOW Study

Carol Moreno MD, PhD¹, Talha Munir MBBS², Carolyn Owen MD³, George Follows MA, BM, BCh, PhD, FRCP, FRCPath⁴, José-Ángel Hernández-Rivas MD, PhD⁵, Ohad Benjamini MD⁶, Ann Janssens MD, PhD⁷, Mark-David Levin MD⁸, Tadeusz Robak MD, PhD⁹, Martin Simkovic MD, PhD¹⁰, Sergey Voloshin MD, PhD¹¹, Vladimir Vorobyev PhD¹², Munci Yagci MD¹³, Loic Ysebaert MD, PhD¹⁴, Qianya Qi PhD¹⁵, Emma Smith MBChB, DPM¹⁵, Srimathi Srinivasan PhD¹⁶, Natasha Schuier MD¹⁷, Kurt Baeten PhD¹⁸, Donne Bennett Caces MD, PhD¹⁵, Carsten Niemann MD, PhD¹⁹, Arnon Kater MD, PhD²⁰

¹Hospital de la Santa Creu i Sant Pau, Autonomous University of Barcelona, Josep Carreras Leukaemia Research Institute, Barcelona, Spain. ²St James's Hospital, Leeds, United Kingdom. ³Tom Baker Cancer Centre, Calgary, Canada. ⁴Addenbrookes Hospital, Cambridge, United Kingdom. ⁵Hospital Universitario Infanta Leonor, Universidad Complutense, Madrid, Spain. ⁶Sheba Medical Center, Ramat Gan, Israel. ⁷Universitaire Ziekenhuizen Leuven, Leuven, Belgium. ⁸Albert Schweitzer Hospital, Dordrecht, Netherlands. ⁹Medical University of Lodz, Copernicus Memorial Hospital, Lodz, Poland. ¹⁰4th Department of Internal Medicine – Haematology, Faculty of Medicine in Hradec Králové, University Hospital and Charles University in Prague, Hradec Kralove, Czech Republic. ¹¹Russian Scientific and Research Institute of Hematology and Transfusiology, St. Petersburg, Russian Federation. ¹²S.P. Botkin Moscow City Clinical Hospital, Moscow, Russian Federation. ¹³Gazi Üniversitesi Tıp Fakültesi, Ankara, Turkey. ¹⁴Institut Universitaire du Cancer Toulouse Oncopole, Toulouse, France. ¹⁵Janssen Research & Development, Raritan, USA. ¹⁶Oncology Translational Research, Janssen Research & Development, Lower Gwynedd Township, USA. ¹⁷Janssen Research & Development, Düsseldorf, Germany. ¹⁸Janssen Research & Development, Beerse, Belgium. ¹⁹Rigshospitalet Copenhagen University Hospital, Copenhagen, Denmark. ²⁰Amsterdam University Medical Centers, Cancer Center Amsterdam, University of Amsterdam, Amsterdam, Netherlands

POSTER: CLL-495

Treatment Characteristics and Outcomes of Patients With Chronic/Small Lymphocytic Leukemia (CLL) Treated With Venetoclax and Bruton Tyrosine Kinase Inhibitor (BTKi) Combination Therapies

Hande H. Tuncer MD¹, Nilanjan Ghosh MD², Isabelle Fleury MD³, Lori A. Leslie MD⁴, Beenish S. Manzoor PhD⁵, Nicole Lamanna MD⁶, Toby A. Eyre MD⁷, Brian T. Hill MD⁸, Jennifer R. Brown MD¹, Wendy Sinai PharmD⁵, Catherine C. Coombs MD⁹, Chaitra Ujjani MD¹⁰, Lindsey E. Roeker MD¹¹, Nnadozie Emechebe PhD⁵, Paul M. Barr MD¹², Matthew S. Davids MD¹, Nicolas Martinez-Calle MD¹³, Joanna M. Rhodes MD¹⁴, Frederick Lansigan MD¹⁵, Laurie Pearson MD¹⁶, Yun Choi MD¹⁷, Stephen J. Schuster MD¹⁸, Alan P. Skarbnik MD¹⁹, Bitia Fakhri MD²⁰, Michael Coyle MD²¹, Deborah M. Stephens DO²², Meghan C. Thompson MD¹¹, Christopher E. Jensen MD²², Steven E. Marx PharmD⁵, Dureshahwar Jawaid MPH⁵, Anna Schuh MD, PhD⁷, Irina Pivneva PhD²³, Talissa Watson MSc²³, Annie Guerin MSc²³, Mazyar Shadman MD⁹

¹Dana-Farber Cancer Institute, Boston, USA. ²Levine Cancer Institute/Atrium Health, Charlotte, USA. ³Hôpital Maisonneuve-Rosemont, University of Montreal, Montreal, Canada. ⁴John Theurer Cancer Center, Hackensack Meridian Health, Hackensack, USA. ⁵AbbVie, Inc., North Chicago, USA. ⁶Columbia University, New York, USA. ⁷Churchill Hospital, Oxford University, Oxford, United Kingdom. ⁸Cleveland Clinic, Cleveland, USA. ⁹University of California Irvine, Irvine, USA. ¹⁰Fred Hutchinson Cancer Research Center, Seattle, USA. ¹¹CLL Program, Leukemia Service, Division of Hematologic Oncology, Memorial Sloan Kettering Cancer Center, New York, USA. ¹²Wilmut Cancer Institute, University of Rochester Medical Center, Rochester, USA. ¹³Nottingham University Hospitals, NHS Trust, Nottingham, United Kingdom. ¹⁴Rutgers Cancer Institute of New Jersey, New Brunswick, USA. ¹⁵Dartmouth-Hitchcock Medical Center, Lebanon, USA. ¹⁶University of Massachusetts, Worcester, USA. ¹⁷Tufts Medical Center, Boston, USA. ¹⁸University of Pennsylvania, Philadelphia, USA. ¹⁹Lymphoma and CLL Program, Novant Health Cancer Institute, Charlotte, USA. ²⁰Stanford Cancer Institute, Stanford University, Stanford, USA. ²¹Lowell General Hospital, Worcester, USA. ²²Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, USA. ²³Analysis Group, Inc., Montreal, Canada

POSTER: CLL-533

Adverse Events During Single-Agent Phase of Venetoclax Therapy

Ginevra Parodi MD¹, Sabrina Habib MBBS², Sasha Marks MBBS, BSc, PhD², Thomas Lofaro MD, MRCP, FRCPath¹

¹London North West University Healthcare NHS Trust, London, United Kingdom. ²Imperial College Healthcare NHS Trust, London, United Kingdom